Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.
Publication
, Journal Article
McGrail, DJ; Pilié, PG; Rashid, NU; Voorwerk, L; Slagter, M; Kok, M; Jonasch, E; Khasraw, M; Heimberger, AB; Ueno, NT; Ferrarotto, R; Lin, S-Y ...
Published in: Ann Oncol
November 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
November 2022
Volume
33
Issue
11
Start / End Page
1204 / 1206
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasms
- Mutation
- Lung Neoplasms
- Immune Checkpoint Inhibitors
- Humans
- Carcinoma, Non-Small-Cell Lung
- Biomarkers, Tumor
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., … Lin, S.-Y. (2022). Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol, 33(11), 1204–1206. https://doi.org/10.1016/j.annonc.2022.07.009
McGrail, D. J., P. G. Pilié, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, et al. “Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.” Ann Oncol 33, no. 11 (November 2022): 1204–6. https://doi.org/10.1016/j.annonc.2022.07.009.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, et al. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol. 2022 Nov;33(11):1204–6.
McGrail, D. J., et al. “Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.” Ann Oncol, vol. 33, no. 11, Nov. 2022, pp. 1204–06. Pubmed, doi:10.1016/j.annonc.2022.07.009.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin S-Y. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol. 2022 Nov;33(11):1204–1206.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
November 2022
Volume
33
Issue
11
Start / End Page
1204 / 1206
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- Neoplasms
- Mutation
- Lung Neoplasms
- Immune Checkpoint Inhibitors
- Humans
- Carcinoma, Non-Small-Cell Lung
- Biomarkers, Tumor
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences